Heart/Mediastinal Ratio Study for Potential Equivalence of Heart/Mediastinal Ratios at One and Two Hours to the Traditional Heart/Mediastinal Ratio Obtained at Four Hours
NCT01448083 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40
Last updated 2012-09-18
Summary
The purpose of this study is to determine if the measurement (with a standard nuclear camera) of radioactivity normally present in the nervous system of your heart at four hours after the injection of radioactive drug for your diagnostic I-123 MIBG scan is any different than radioactivity measured in your heart at one and/or two hours after your diagnostic scan injection. If equivalent information to the conventional 4 hr H/M ratio could be collected by obtaining H/M ratios at 1 or 2 hour windows, it would greatly facilitate patient acceptance of the procedure since the requirements for obtaining a valid H/M ratio would be considerably less time-consuming.
One hour before being injected with the drug (I-123 MIBG) for your MIBG scan, you will be given a standard dose of non-radioactive iodine (Lugol's solution) to block your thyroid from receiving the small amount of radiation that is a normal part of the MIBG scan. You will then be injected with MIBG, and you will have 10 minute pictures of your chest at 15 minutes, 1 hour, 2 hours, and 4 hours in addition to the standard 24 hour pictures. These pictures will be taken in the Nuclear Medicine Section, Department of Radiology at Ochsner Medical Center-Kenner. The experimental (research) part of this study is having the extra 10-minute pictures of your chest at 15 minutes, 1 hour, 2 hours, and 4 hours. Normally, pictures are only taken 24 hours after the injection. Therefore the research is limited to the four extra pictures taken, and involve no additional injections or I-123 drug beyond that you will be receiving regardless of whether you are part of this research.
Conditions
- Neuroendocrine Tumor
Interventions
- OTHER
-
Standard of care diagnostic MIBG scan for neuroendocrine tumor diagnosis.
Each subject will receive a 370 MBq (10 mCi ) (±10%) injection of I- 123 MIBG. Myocardial I-123 MIBG uptake will be quantitatively measured over time via planar imaging acquired at 15 minutes, one, two, four, and at 24 hours (the standard of care time point for NET patient imaging) post I-123MIBG injection.
Sponsors & Collaborators
-
Nuclear Medicine Consultants, Inc.
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-10-31
Countries
- United States
Study Locations
More Related Trials
-
Multimodality- Adapted Dose Modification in Head and Neck Cancer Radiation Therapy 
NCT04933357 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Radiation Induced Cardiopulmonary Injury in Humans
NCT02259452 ·Status: TERMINATED
-
MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial
NCT05975593 ·Status: RECRUITING ·Phase: NA
-
A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer
NCT02454010 ·Status: COMPLETED ·Phase: PHASE1
-
Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients
NCT04917484 ·Status: RECRUITING ·Phase: PHASE2
-
Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes
NCT04183218 ·Status: COMPLETED
-
Individualized Response-adaptive Radiation Dose Prescription in HNC Based on MRI
NCT05160714 ·Status: UNKNOWN ·Phase: PHASE1
-
Total Body Composition in Detection of Nutrition Depletion in Head and Neck Patients
NCT02854735 ·Status: UNKNOWN
-
Evaluation of a New CZT System
NCT01084356 ·Status: UNKNOWN
-
Intra- and Inter-fraction Changes in Radiation Therapy
NCT02344121 ·Status: RECRUITING
-
Multimodal Assesment of Acute Cardiac Toxicity Induced by Thoracic Radiotherapy in Cancer Patients
NCT04896242 ·Status: COMPLETED
-
Assessment of Early Radiation Oncology Involvement Alongside Standard Oncologic Care in the Managemet
NCT05351294 ·Status: SUSPENDED ·Phase: PHASE3
-
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
NCT04665739 ·Status: RECRUITING ·Phase: PHASE2
-
Combination Targeted Radiotherapy in Neuroendocrine Tumors
NCT01099228 ·Status: COMPLETED ·Phase: NA
-
Monitoring Radiobiological Effects in Thoracic Malignancy by Using Myocardial Perfusion Scan
NCT01913769 ·Status: UNKNOWN
-
Repeat CT for Evaluation of Inter- and Intrafraction Changes During Curative Thoracic Radiotherapy
NCT03024138 ·Status: COMPLETED
-
Adaptive, Image-guided, Intensity-modulated Radiotherapy for Head and Neck Cancer in the Reduced Volumes of Elective Neck
NCT01287390 ·Status: COMPLETED ·Phase: PHASE2
-
A Pilot Trial of Image-Guided Adaptive Radiotherapy for Head and Neck Cancer
NCT00490282 ·Status: COMPLETED ·Phase: NA
-
Personalized Estimation of Doses Delivered During Image Guided Radiation Therapy Tests
NCT05258383 ·Status: UNKNOWN
-
Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer
NCT00471835 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
A Study of Patients Receiving High-Dose Rate Brachytherapy
NCT00924027 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Optical Imaging With Light From Radiotracers in Cancer Patients
NCT03484884 ·Status: ACTIVE_NOT_RECRUITING
-
The Use of Breathing Synchronized CT and PET Scans in Radiation Therapy Treatment Planning
NCT00588328 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Cancer.
NCT01124409 ·Status: UNKNOWN ·Phase: PHASE3
-
MRI Guided Radiotherapy and Radiobiological Data: the ISRAR Database (Irm Sequences for Radiobiological Adaptative Radiotherapy)
NCT06041555 ·Status: RECRUITING